Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 444 across all filing types
Latest filing 2024-07-01 Regulatory Filings
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Admission of the Second Tranche Placing Shares
Regulatory Filings Classification · 98% confidence The document is identified by the RNS Number header and contains information typical of a regulatory news service announcement from the London Stock Exchange. The content specifically discusses the admission to trading of 'Second Tranche Placing Shares' following previous financing announcements, which relates to capital structure changes and share issuance. Although it touches upon capital (CAP), the primary function of this specific RNS release is to formally announce a corporate action related to shares being admitted to trading, which is a type of regulatory disclosure. Furthermore, the document concludes with standard RNS boilerplate text, indicating it is a general regulatory announcement. Since the core event is the admission of new shares, it strongly aligns with 'Share Issue/Capital Change' (SHA). However, given the context of it being a formal RNS announcement detailing the final step of a share placement, and the presence of Takeover Code disclosure requirements (which often accompany capital changes or M&A), the most precise fit among the provided options that covers specific corporate actions announced via RNS is SHA. If SHA were not available, RNS would be the fallback. Since it is about the admission of newly issued shares, SHA is the best fit.
2024-07-01 English
Nasdaq Delisting Determination - Appeal update
Delisting Announcement Classification · 100% confidence The document is identified by the 'RNS Number' header and the closing statement referencing 'RNS, the news service of the London Stock Exchange'. The core content announces that Renalytix has submitted a hearing request to the Nasdaq Hearings Panel regarding a 'Staff Delisting Determination'. This action is a direct response to non-compliance with Nasdaq listing rules (minimum bid price and market value). A delisting determination and the subsequent appeal/hearing process are critical regulatory events concerning the company's listing status. While the subject matter relates to a potential delisting (DLST), the document itself is a formal announcement disseminated via the Regulatory News Service (RNS) detailing this specific corporate action and its immediate regulatory consequence (staying the suspension). Since the primary action is the formal notification of a significant regulatory event via the RNS system, and it doesn't fit perfectly into the specific categories like 'DEF 14A' or '10-K', the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly branded as an RNS release.
2024-06-28 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (4054 characters) and its primary purpose is to announce a specific piece of corporate information: the 'Total Voting Rights' as of a specific date (June 28, 2024). It explicitly states the total number of issued shares and notes that this figure can be used by shareholders for Disclosure Guidance and Transparency Rule calculations. This type of mandatory, periodic disclosure regarding the total share capital and voting rights is a standard regulatory announcement. Since it is not a comprehensive report (like 10-K or IR) but a specific, brief update disseminated via RNS, it fits best under the general 'Regulatory Filings' category (RNS) as it is a formal notification required by the exchange/regulator, rather than a specific category like DIV or DIRS. It is not an announcement *about* a report, but the report itself (a short regulatory notice).
2024-06-28 English
Change of public accounting firm
Board/Management Information Classification · 99% confidence The document is a short announcement (4101 characters) released via RNS (London Stock Exchange news service). The primary content announces a 'Change of public accounting firm,' specifically the appointment of CohnReznick LLP and the dismissal of Ernst & Young LLP. This type of corporate action announcement, which is not a full financial report (like 10-K or IR) or a specific management/director change, falls best under the general category for regulatory announcements that do not fit elsewhere, which is Regulatory Filings (RNS). It is not a Director's Dealing (DIRS), Management Change (MANG), or a specific financial filing type.
2024-06-25 English
Receipt of Nasdaq Delisting Determination - Appeal
Delisting Announcement Classification · 100% confidence The document is an RNS announcement (indicated by the RNS Number header and the footer referencing RNS/LSE) detailing that Renalytix plc received a Nasdaq Delisting Determination and plans to appeal. This is a specific corporate action announcement regarding regulatory compliance with a stock exchange, which is not covered by the more specific categories like 10-K, ER, or DIV. While it mentions the SEC and Form 25-NSE, the primary purpose is the immediate public disclosure of the delisting notice and appeal plan via the RNS system. Since it is a specific regulatory/exchange event announcement that doesn't fit the other defined categories (like DVA, DLST, or LTR), the most appropriate general regulatory announcement category is RNS (Regulatory Filings), as it is a standard market disclosure.
2024-06-25 English
Medicare issues final Local Coverage Determination
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS announcement (RNS Number : 4910S) from Renalytix PLC, dated June 14, 2024. It announces a significant business development: Medicare issuing a final Local Coverage Determination (LCD) for their kidneyintelX.dkd test. This type of announcement, detailing a specific operational or regulatory milestone (like insurance coverage approval) and often containing forward-looking statements and contact information, is characteristic of a general regulatory news service release. Since it is an announcement of a specific event rather than a comprehensive periodic report (like 10-K or IR) or a transcript, and it is distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such market-sensitive news releases not covered by more specific codes like ER or DIV. The document length is substantial (7500 chars), but its nature is that of a press release distributed via an RNS service.
2024-06-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.